Late presentation for HIV remains a major health issue in Spain: Results from a multicenter cohort study, 2004–2018

Marta Rava1,*, Lourdes Domínguez-Domínguez2,*, Otilia Bisbal2, Luis Fernando López-Cortés3, Carmen Busca4, Antonio Antela5, Patricia González-Ruano6, Cristina Hernández7, José-Antonio Iribarren8, Rafael Rubio2, Santiago Moreno9,†, Inmaculada Jarrín†,‡, Cohort of the Spanish HIV/AIDS Research Network (CoRIS)†,‡

1 Unit AIDS Research Network Cohort (CoRIS), National Center of Epidemiology (CNE), Health Institute Carlos III (ISCIII), Madrid, Spain, 2 12 de Octubre University Hospital, Madrid, Spain, 3 Virgen del Rocío University Hospital, Sevilla, Spain, 4 La Paz University Hospital, Madrid, Spain, 5 University Clinical Hospital of Santiago de Compostela, Santiago de Compostela, Spain, 6 Infanta Sofía University Hospital, Madrid, Spain, 7 Príncipe de Asturias University Hospital, Alcalá de Henares, Madrid, Spain, 8 Department of Infectious Diseases, University Hospital, IIS Biodonostia, San Sebastián, Spain, 9 Ramón y Cajal University Hospital, Madrid, Spain

These authors contributed equally to this work.
† These authors also contributed equally to this work.
‡ Membership of the Cohort of the Spanish HIV/AIDS Research Network (CoRIS) is listed in the Acknowledgments.
* mrava@isciii.es

Abstract

Objectives

With the purpose of reducing the well-known negative impact of late presentation (LP) on people living with HIV (PLWH), guidelines on early HIV diagnosis were published in 2014 in Spain, but since then no data on LP prevalence have been published. To estimate prevalence and risk factors of LP and to evaluate their impact on the development of clinical outcomes in the Cohort of the Spanish HIV/AIDS Research Network (CoRIS) during 2004–2018.

Methods

CoRIS is an open prospective multicenter cohort of PLWH, adults, naive to ART at entry. LP was defined as HIV diagnosis with CD4 count $\leq$ 350 cells/µL or an AIDS defining event (ADE). Multivariable Poisson regression models were used to estimate both prevalence ratios (PR) for the association of potential risk factors with LP and Incidence rate ratios (IRRs) for its impact on the development of the composite endpoint (first ADE, first serious non-AIDS event [SNAE] or overall mortality).

Results

14,876 individuals were included. Overall, LP prevalence in 2004–2018 was 44.6%. Risk factors for LP included older age, having been infected through injection drug use or heterosexual intercourse, low educational level and originating from non-European countries. LP
was associated with an increased risk of the composite endpoint (IRR: 1.34; 95% CI 1.20, 1.50), ADE (1.39; 1.18, 1.64), SNAE (1.22; 1.01, 1.47) and mortality (1.71; 1.41, 2.08).

Conclusions
LP remains a health problem in Spain, mainly among certain populations, and is associated with greater morbidity and mortality. Public policies should be implemented to expand screening and early diagnosis of HIV infection, for a focus on those at greatest risk of LP.

Introduction
Late presentation (LP) of HIV infection represents an important barrier in achieving the UNAIDS goals to end AIDS epidemic by 2030. Despite multiple efforts to establish strategies to improve the early diagnosis of HIV infection, the prevalence of LP remains high (between 40–60% in developed countries [1–3] and higher in developing countries [4]) and has not decreased during the last years. In Spain, results from the most recent study within the Cohort of the Spanish HIV/AIDS Research Network (CoRIS) showed an overall LP prevalence of 46.9% from 2004 to 2013 [5]. According to the last treatment cascade estimates [6], 13% of people living with HIV in Spain are unaware of it. Of those diagnosed, 97.3% were on ART, of whom 90.4% had an undetectable viral load. In 2014 the Spanish Ministry of Health published national guidelines for promoting early HIV diagnosis [7]. They recommended offering HIV testing when there is an indication or clinical suspicion of HIV infection or AIDS but also recommended routine offer of HIV screening. So far, there is no information on whether the implementation of these guidelines have had an impact on LP prevalence.

The implications of LP are widespread: increased risk of morbidity and mortality [8, 9], suboptimal virologic and immunologic effectiveness of antiretroviral therapy [10], increased risk of transmission due to lack of awareness of HIV serostatus [11, 12] as well as higher negative impact on healthcare costs [13]. However, while it is clear that LP carries a risk for the development of AIDS-related diseases and death, [5] its relationship with the development of non-AIDS diseases is less clear, based only on studies that relate poor immunologic status to its development. To the best of our knowledge, there are very few studies that directly evaluate LP as a risk factor for the development of non-AIDS events.

Therefore, the aims of this study are (i) to estimate the prevalence and associated risk factors of LP and late presentation with advanced disease (LPAD) and their changes over time in the period 2004–2018, and (ii) to estimate the impact of LP and LPAD on the development of clinical outcomes including AIDS-defining events (ADE), serious non-AIDS events (SNAE) and mortality in participants from the CoRIS cohort.

Materials and methods
Study population
CoRIS is an open, prospective, multicenter cohort of subjects with confirmed HIV infection, naïve to ART at study entry. Participants are recruited in 46 centers from 13 of the 17 autonomous regions in Spain from 2004 onwards. Administrative censoring date for these analyses was 30 November 2018. A complete description of CoRIS has been published in 2007 [14]. The study was approved by the Research Ethic Committee of the Instituto de Salud Carlos III.
and was conducted in accordance with the Declaration of Helsinki. All patients gave their written informed consent.

Briefly, CoRIS collects a minimum dataset which includes baseline and follow-up socio-demographic, immunologic and clinical data, including ART medication. Data are highly standardized and are submitted for periodic quality control procedures. Patients are followed-up periodically in accordance with routine clinical practice. All patients undergo blood collection for immunologic analysis, including CD4+ and CD8+ T lymphocyte quantification. Furthermore, all centers are invited to provide data on incident ADE and non-AIDS events, including non-AIDS–defining malignancies and cardiovascular, renal, liver, psychiatric, bone, and metabolic events.

The study population includes all CoRIS participants, aged ≥18 years recruited from 1 January 2004 to 30 November 2018 who had available information on CD4 count or ADE between 4 weeks before and 24 weeks after enrolment. For analyses on association of LP and LPAD with first occurrence of clinical events, individuals followed-up for less than six months were excluded from the relevant analysis. Individuals monitored in centers not providing data on NAEs were excluded for the relevant analyses.

**Definitions of late presentation and late presentation with advanced disease**

Using the consensus definition [15], LP was defined as an HIV-diagnosis at a CD4 count below 350 cells/µL between 4 weeks before and 24 weeks after enrolment or with an AIDS-defining event within the first 24 weeks after enrolment, both conditions met before ART initiation. Participants with LPAD were a subgroup of those with LP, with an HIV diagnosis at a CD4 count <200 cells/µL between 4 weeks before and 24 weeks after enrolment.

**Health outcomes**

The primary composite endpoint was first ADE, first SNAE or death from any cause occurred from 6 months after enrolment.

SNAE consisted of the following conditions: cardiovascular disease (myocardial infarction, angina, heart disease, transient ischemic attack, reversible ischemic deficit, stroke and peripheral arteriopathy) or death from cardiovascular disease, renal disease (end-stage renal disease, initiation of dialysis or renal transplantation) or death from renal disease, liver disease (ascites, gastrointestinal hemorrhage due to esophageal varices, hepatic encephalopathy, liver transplantation) or death from liver disease, non-AIDS-defining cancer or death from non-AIDS-defining cancer, and infectious-related deaths.

**Statistical methods**

Variables were summarized as medians and interquartile ranges (IQR) when continuous, and as percentages when categorical. Multivariable Poisson regression models with robust standard errors estimates [16] were used to estimate prevalence ratios (PRs) and 95% confidence intervals (CI) for the association of potential risk factors for LP and LPAD: in all these models we compared participants with LP vs those without LP (non-LP, CD4 count ≥350 cells/µL and no AIDS-defining event) and participants with LPAD with those without LPAD (non-LPAD, CD4 count ≥200 cells/µL and no AIDS-defining event). Variables included were: a combined variable of gender and HIV transmission category (men who have sex with men [MSM], injection drug users [IDU], heterosexual men, heterosexual women and other/unknown), age at enrolment (<30, 30–49, ≥50 years), educational level (none or primary education only, secondary education, university, other/unknown) and region of origin (Europe, Sub-Saharan...
Africa [SSA], Latin America [LA], other/unknown). To assess whether risk factors for LP and LPAD had changed over time, interaction terms between each risk factor and the time-period (2004–2008, 2009–2012 and 2013–2018) were included in the multivariable models. The same model was used to obtain prevalence of LP and LPAD adjusted for a combined variable of gender and HIV transmission category, age at enrolment, educational level and region of origin.

Incidence rates for the composite endpoint, the first ADE, the first SNAE and death from any cause were calculated as the number of new cases occurred after six months from enrolment divided by the total person-years at risk from six months after enrolment until the first event, last follow-up visit or death, whichever came first. Incidence rate ratios (IRRs) and 95% CI for the association between LP and LPAD and the development of the composite endpoint and its components were estimated with multivariable Poisson regression models with person-time at risk as the offset variable and robust standard error estimates accounting for clusters between centers. All models were adjusted for the combined variable of gender and HIV transmission category, educational level, region of origin and age, presence of hepatitis C virus (HCV) antibodies (no, yes or unknown), presence of hepatitis B virus surface antigen (HBsAg, no, yes or unknown) and viral load (<10,000, 10,000–100,000, \( \geq 100,000 \) copies/mL or unknown) at enrolment.

All statistical analyses were performed using R version 4.0 [17].

Sensitivity analyses
We performed sensitivity analyses using different definitions of LP and LPAD as HIV-diagnosis at a CD4 <350 cells/µL (for LP) or <200 cells/µL (for LPAD) or with an ADE in the first 4, 12 or 48 weeks after enrolment.

Results
Of the 15,509 antiretroviral naïve individuals enrolled in CoRIS until the 30th November 2018, 14,876 individuals were included (S1 Fig) of whom 12,652 (85.0%) were men, 9,182 (61.7%) were MSM, 3,742 (25.2%) had a university degree and 10,800 (72.6%) were from Europe, mostly from Spain (8,725, 58.7%). At enrolment, median age was 35.2 years (1st-3rd quartile: 28.9, 42.9), median CD4 count was 397 cells/µL (215, 592), 1,961 (13.2%) individuals had an AIDS diagnosis and 5,102 (34.3%) had a viral load \( \geq 100,000 \) copies/mL (Table 1).

Late presentation and late presentation with advanced disease: Magnitude, trends and risk factors
Total number of late presenters was 6,636 (prevalence 44.6%; 95%CI 43.8, 45.4) and of late presenters with advanced disease was 3,931 (26.4%; 95%CI 25.7, 27.1). Annual prevalence of LP and LPAD is shown in Fig 1. In 2004–2008 the prevalence of LP was 51.8% (95%CI 50.4, 53.3); it decreased to 40.9% (95%CI 39.4, 42.4) in 2009–2012 and remained stable at 42.0% (95%CI 40.8, 43.2) during 2013–2018 (p-value for trend <0.001). Likewise, the prevalence of LPAD decreased from 33.9% (95%CI 32.5, 35.3) in 2004–2008 to 22.7% (95%CI 21.5, 24.0) in 2009–2012 and remained stable with a modest increase up to 23.6% (95%CI 22.6, 24.7) during 2013–2018 (p-value for trend<0.001).

Among individuals older than 50 years, prevalence of LP was 63.8% and of LPAD was 46.5% (Table 1). Around 60% of IDU and of heterosexual men had LP and more than 40% had LPAD. Among persons originating from SSA, prevalence of LP was almost 60% and prevalence of LPAD was around 35%. Around 60% and of persons with primary or less educational level had LP and around 39% had LPAD.
Table 1. Sociodemographic and clinical characteristics of the participants included, and prevalence of late presentation and late presentation with advanced disease according to their characteristics at enrolment, Spain, 2004–2018 (n = 14,876).

| Overall, N = 14,876 | Late presentation, N = 6,636 (44.6%) | Late presentation with advanced disease, N = 3,931 (26.4%) |
|---------------------|--------------------------------------|----------------------------------------------------------|
| [N (%)]             | [N (row %)]                          | [N (row %)]                                               |
| **Sex**             |                                      |                                                          |
| Females             | 2,224 (15.0%)                        | 1,176 (52.9%)                                            | 761 (34.2%)                      |
| Males               | 12,652 (85.0%)                       | 5,460 (43.2%)                                            | 3,170 (25.1%)                    |
| **Age (year)**      |                                      |                                                          |
| Median [1st, 3rd quartile] | 35.2 (28.9, 42.9)                  |                                                          |
| <30                 | 3,720 (25.0%)                        | 1,199 (32.2%)                                            | 507 (13.6%)                      |
| 30–49               | 9,326 (62.7%)                        | 4,269 (45.8%)                                            | 2,573 (27.6%)                    |
| ≥50                 | 1,830 (12.3%)                        | 1,168 (63.8%)                                            | 851 (46.5%)                      |
| **Transmission group** |                                   |                                                          |
| MSM                 | 9,182 (61.7%)                        | 3,344 (36.4%)                                            | 1,685 (18.4%)                    |
| IDU                 | 1,090 (7.3%)                         | 658 (60.4%)                                              | 449 (41.2%)                      |
| Heterosexual women | 1,894 (12.7%)                        | 999 (52.7%)                                              | 643 (33.9%)                      |
| Heterosexual men   | 2,177 (14.6%)                        | 1,297 (63.8%)                                            | 906 (41.6%)                      |
| Other/unknown      | 533 (3.6%)                           | 64 (12.3%)                                               | 48 (8.9%)                       |
| **Education level** |                                      |                                                          |
| None or primary education only | 1,864 (12.5%) | 1,103 (59.2%)                                            | 730 (39.2%)                      |
| Secondary education | 6,801 (45.7%)                        | 2,923 (43.0%)                                            | 1,758 (25.8%)                    |
| University         | 3,742 (25.2%)                        | 1,349 (36.1%)                                            | 650 (17.4%)                      |
| Other/unknown      | 2,469 (16.6%)                        | 1,261 (51.1%)                                            | 793 (32.1%)                      |
| **Region of origin** |                                     |                                                          |
| Europe             | 10,800 (72.6%)                       | 4,609 (42.7%)                                            | 2,749 (25.5%)                    |
| Sub-Saharan Africa | 685 (4.6%)                           | 407 (59.4%)                                              | 251 (36.6%)                      |
| Latin America      | 3,083 (20.7%)                        | 1,465 (47.5%)                                            | 822 (26.7%)                      |
| Other/unknown      | 308 (2.1%)                           | 155 (50.3%)                                              | 109 (35.4%)                      |
| **CD4 count, cells/μL** |                                   |                                                          |
| Median [1st; 3rd quartile] | 397 [215; 592]                  |                                                          |
| **AIDS-defining event** |                                   |                                                          |
| No                 | 12,915 (86.8%)                       | 4,675 (36.2%)                                            | 1,970 (15.3%)                    |
| Yes                | 1,961 (13.2%)                        | 1,961 (100.0%)                                           | 1,961 (100.0%)                  |
| **Viral load, copies/mL** |                                   |                                                          |
| <10,000            | 3,076 (20.7%)                        | 668 (21.7%)                                              | 259 (8.4%)                       |
| 10,000–100,000     | 6,238 (41.9%)                        | 2,320 (37.2%)                                            | 1,031 (16.5%)                    |
| ≥100,000           | 5,102 (34.3%)                        | 3,295 (64.6%)                                            | 2,348 (46.0%)                    |
| Unknown            | 460 (3.1%)                           | 353 (76.7%)                                              | 293 (63.7%)                      |
| **HCV antibodies** |                                      |                                                          |
| No                 | 11,676 (78.5%)                       | 5,013 (42.9%)                                            | 2,868 (24.6%)                    |
| Yes                | 1,468 (9.9%)                         | 845 (57.6%)                                              | 564 (38.4%)                      |
| Unknown            | 1,732 (11.6%)                        | 778 (44.9%)                                              | 499 (28.8%)                      |
| **HBsAg** |                                   |                                                          |
| No                 | 9,169 (61.6%)                        | 3,856 (42.1%)                                            | 2,189 (23.9%)                    |
| Yes                | 3,955 (26.6%)                        | 1,997 (50.5%)                                            | 1,236 (31.3%)                    |
| Unknown            | 1,752 (11.8%)                        | 783 (44.7%)                                              | 506 (28.9%)                      |
| **Year**           |                                      |                                                          |
| 2004–2008          | 4,434 (29.8%)                        | 2,296 (51.8%)                                            | 1,502 (33.9%)                    |

(Continued)
Independent risk factors for LP compared to non-LP (Table 2) included older age (adjusted PR 1.36; 95%CI 1.30, 1.43 for 30–49 years and 1.77; 95%CI 1.65, 1.89 for ≥50 years vs <30 years) and transmission category, with IDU (aPR 1.49; 95%CI 1.33, 1.68), heterosexual men (aPR 1.41; 95%CI 1.27, 1.57) and heterosexual women (aPR 1.27; 95%CI 1.15, 1.41) having higher risks of LP compared to MSM. Other risk factors for LP were low educational level (aPR 1.31; 95%CI 1.20, 1.43 for primary education and 1.09; 95%CI 1.04, 1.14 for secondary education vs university) and region of origin with individuals originating from SSA (aPR 1.17; 95%CI 1.10, 1.25) and LA (aPR 1.23; 95%CI 1.16, 1.30) showing a higher risk of LP than Europeans. Similar risk factors were observed when we compared participants with LPAD with those without (Table 2).

Overall risk factors for LP and LPAD were confirmed during the three time periods considered (S1 Table). Nevertheless, adjusted LP prevalence were not homogeneous across transmission categories, as shown in Fig 2. Specifically, the adjusted prevalence of LP decreased from 28.4% in 2004–2008 to 22.6% in 2009–2012 in MSM and from 37.6% in 2004–2008 to 32.3% in 2009–2012 in heterosexual men, while adjusted LP prevalence in heterosexual women remained stable around 30%-33% during the whole 15-years period. Furthermore, while adjusted LP prevalence in MSM and heterosexual men, after an initial decrease from 2004–

![Graph showing annual prevalence of LP and LPAD, 2004–2018](https://doi.org/10.1371/journal.pone.0249864.g001)

**Table 1. (Continued)**

|                | Overall, N = 14,876 | Late presentation, N = 6,636 (44.6%) | Late presentation with advanced disease, N = 3,931 (26.4%) |
|----------------|---------------------|---------------------------------------|----------------------------------------------------------|
| 2009–2012      | 4,168 (28.0%)       | 1,705 (40.9%)                         | 947 (22.7%)                                              |
| 2013–2018      | 6,274 (42.2%)       | 2,635 (42.0%)                         | 1,482 (23.6%)                                           |

MSM: men who have sex with men, IDU: injection drug users, HCV: hepatitis C virus, HBsAg: hepatitis B surface antigen.

https://doi.org/10.1371/journal.pone.0249864.t001
2008 to 2009–2012, remained stable during 2013–2018, adjusted LP prevalence in IDU continued to decrease from 39.4% in 2004–2008 to 34.3% in 2009–2012 to 30.1% in 2013–2018.

Impact of late presentation and late presentation with advanced disease on morbidity and mortality

Of 14,876 participants, 13,031 (87.6%) had available follow-up data: 5,790 (87.3%) had LP and 3,412 (86.8%) had LPAD, with a total of 69,142 person-years (PY) of follow-up. Table 3 shows the number of participants experiencing each outcome, incidence rates (IR) per 100 PY of follow-up and incidence rate ratios for LP and LPAD.

2008 to 2009–2012, remained stable during 2013–2018, adjusted LP prevalence in IDU continued to decrease from 39.4% in 2004–2008 to 34.3% in 2009–2012 to 30.1% in 2013–2018.

Impact of late presentation and late presentation with advanced disease on morbidity and mortality

Of 14,876 participants, 13,031 (87.6%) had available follow-up data: 5,790 (87.3%) had LP and 3,412 (86.8%) had LPAD, with a total of 69,142 person-years (PY) of follow-up. Table 3 shows the number of participants experiencing each outcome, incidence rates (IR) per 100 PY of follow-up and incidence rate ratios for LP and LPAD.

Overall, 435 non-late presenters and 726 late presenters experienced any of the events defined by the composite endpoint, with an IR of 1.21 (95%CI 1.10, 1.33) x100 PY in non-late presenters and of 2.34 (95%CI 2.17, 2.52) in late presenters, with an adjusted incidence rate ratio (aIRR) of 1.34 (95%CI 1.20, 1.50). IR for first ADE was almost double in participants with LP (IR: 0.99; 95%CI 0.88, 1.12) than in participants who were diagnosed early (IR: 0.51; 95%CI 0.44, 0.59), with an aIRR of 1.39 (95%CI 1.18, 1.64). 406 participants with LP experienced an SNAE with a rate of 1.32 (95%CI 1.19, 1.45) as did 262 participants non-late
Fig 2. Adjusted prevalence of late presentation by transmission category and time-period.

https://doi.org/10.1371/journal.pone.0249864.g002
Late presentation for HIV: A major health issue in Spain

Table 3. Impact of late presentation and late presentation with advanced disease on the composite endpoint, first ADE, first SNAE and overall mortality, Spain, 2004–2018, (N = 13,031 and 69,142 persons-year of follow-up).

| N of events | Follow-up (PYs) | Rate (95% CI) (per 100 PYs) | N of events | Follow-up (PYs) | Rate (95% CI) (per 100 PYs) | Unadjusted IRR (95% CI) \(^a\, ^b\) | p-value | Adjusted IRR (95% CI) \(^a\, ^b\) | p-value |
|-------------|-----------------|-----------------------------|-------------|-----------------|-----------------------------|--------------------------------|---------|--------------------------------|---------|
| Composite endpoint \(^c\) | | | | | | | | | |
| 435 | 36,046 | 1.21 (1.10, 1.33) | 726 | 31,006 | 2.34 (2.17, 2.52) | 1.95 (1.71, 2.22) | < 0.001 | 1.34 (1.20, 1.50) | < 0.001 |
| ADE | 177 | 34,840 | 0.51 (0.44, 0.59) | 295 | 29,653 | 0.99 (0.88, 1.12) | 1.95 (1.58, 2.42) | < 0.001 | 1.39 (1.18, 1.64) | < 0.001 |
| SNAE \(^c\, ^d\) | 262 | 35,519 | 0.73 (0.65, 0.83) | 406 | 30,769 | 1.32 (1.19, 1.45) | 1.80 (1.53, 2.11) | < 0.001 | 1.22 (1.01, 1.47) | 0.039 |
| Cardiovascular event | 85 | 35,752 | 0.24 (0.19, 0.29) | 112 | 31,070 | 0.36 (0.30, 0.43) | 1.52 (1.08, 2.13) | < 0.016 | 0.89 (0.63, 1.27) | 0.534 |
| Liver event | 26 | 35,778 | 0.07 (0.05, 0.11) | 58 | 31,178 | 0.19 (0.14, 0.24) | 2.56 (1.73, 3.78) | < 0.001 | 1.74 (1.12, 2.71) | 0.014 |
| Kidney event | 6 | 35,333 | 0.02 (0.01, 0.04) | 9 | 30,561 | 0.03 (0.01, 0.06) | 1.73 (0.55, 5.45) | 0.346 | 0.84 (0.24, 2.92) | 0.787 |
| Neoplasm | 150 | 34,367 | 0.44 (0.37, 0.51) | 228 | 29,094 | 0.78 (0.69, 0.89) | 1.80 (1.49, 2.17) | < 0.001 | 1.32 (1.08, 1.63) | 0.007 |
| Overall mortality | 132 | 36,886 | 0.36 (0.30, 0.42) | 321 | 32,253 | 1.00 (0.89, 1.11) | 2.78 (2.27, 3.41) | < 0.001 | 1.71 (1.41, 2.08) | < 0.001 |
| Non-late presenter s with advanced disease | | | | | | | | | |
| 600 | 48,361 | 1.24 (1.14, 1.34) | 561 | 18,691 | 3.00 (2.76, 3.26) | 2.42 (2.08, 2.80) | < 0.001 | 1.66 (1.46, 1.89) | < 0.001 |
| ADE | 236 | 46,528 | 0.51 (0.44, 0.58) | 236 | 17,966 | 1.31 (1.15, 1.49) | 2.57 (2.06, 3.20) | < 0.001 | 1.89 (1.61, 2.23) | < 0.001 |
| SNAE \(^c\, ^d\) | 360 | 47,473 | 0.76 (0.68, 0.84) | 307 | 18,815 | 1.63 (1.45, 1.82) | 2.15 (1.81, 2.56) | < 0.001 | 1.45 (1.18, 1.78) | < 0.001 |
| Cardiovascular event | 117 | 47,838 | 0.24 (0.20, 0.29) | 80 | 18,983 | 0.42 (0.33, 0.52) | 1.72 (1.29, 2.30) | < 0.001 | 0.93 (0.71, 1.21) | 0.577 |
| Liver event | 38 | 47,873 | 0.08 (0.06, 0.11) | 46 | 19,084 | 0.24 (0.18, 0.32) | 3.04 (2.08, 4.43) | < 0.001 | 2.13 (1.30, 3.50) | 0.003 |
| Kidney event | 8 | 47,271 | 0.02 (0.01, 0.03) | 7 | 18,622 | 0.04 (0.02, 0.08) | 2.22 (0.80, 6.16) | 0.125 | 1.06 (0.32, 3.50) | 0.918 |
| Neoplasm | 203 | 45,992 | 0.44 (0.38, 0.51) | 175 | 17,469 | 1.00 (0.86, 1.16) | 2.27 (1.87, 2.76) | < 0.001 | 1.70 (1.32, 2.19) | < 0.001 |
| Overall mortality | 197 | 49,456 | 0.40 (0.34, 0.46) | 256 | 19,683 | 1.30 (1.15, 1.47) | 3.27 (2.63, 4.06) | < 0.001 | 2.04 (1.64, 2.54) | < 0.001 |

ADE: AIDS defining event; CI: confidence interval; IRR: incidence rate ratio; LP: late presenters; LPAD: late presenters with advanced disease; PY: person-years; SNAE: serious non-AIDS event.

*IRR (CI 95%) were estimated with Poisson regression models with person-years at risk as the offset variable and robust standard error estimates.

**IRR estimates obtained after adjustment for a combined variable of gender and HIV transmission category (MSM, IDU, heterosexual men, heterosexual women and other/unknown), educational level (None or primary education only, secondary education, university, other/unknown), region of origin (Europe, Sub-Saharan Africa, Latin America, other/unknown), and age (<30, 30–49, ≥50 years), presence of HCV antibodies (no, yes or unknown), presence of HBsAg (no, yes or unknown) and viral load (<10,000, 10,000–100,000, ≥100,000 copies/mL or unknown) at enrolment.

*Individuals who were monitored in centers not providing data on non-AIDS events were excluded.

**The number of specific SNAE do not sum up because one individual can have multiple SNAE.

https://doi.org/10.1371/journal.pone.0249864.t003

Presenters with an IR of 0.73 (95% CI 0.65, 0.83), giving an aIRR of 1.22 (95% CI 1.01, 1.47). LP was associated with an increased risk of liver events (aIRR 1.74; 95% CI 1.12, 2.71), and neoplasms (aIRR 1.32; 95% CI 1.08, 1.63). Higher mortality rates were observed in late presenters (IR: 1.00; 95% CI 0.89, 1.11) than in non-late presenters (IR: 0.36; 95% CI 0.30, 0.42), with an aIRR of 1.71 (95% CI 1.41, 2.08).
561 participants with LPAD and 600 with non-LPAD experienced at least one event defined by the composite endpoint, with an IR of 3.00 (95%CI 2.76, 3.26) in participants with LPAD, an IR of 1.24 (95%CI 1.14, 1.34) in those with non-LPAD, and an aIRR of 1.66 (95%CI 1.46, 1.89). LPAD was associated with increased risk of developing an ADE (aIRR: 1.89; 95%CI 1.61, 2.23) and an SNAE (aIRR: 1.45; 95%CI 1.18, 1.78) and with increased risk of liver events (aIRR: 2.13; 95%CI 1.30, 3.50) and neoplasms (aIRR: 1.70; 95%CI 1.32, 2.19). Finally, participants with LPAD had higher mortality rates (IR: 1.30; 95%CI 1.15, 1.47) than non-late presenters with advanced disease (IR: 0.40; 95%CI 0.34, 0.46) with a two-fold increase in the risk of death (aIRR: 2.04; 95%CI 1.64, 2.54).

Sensitivity analysis

When LP was defined as CD4 count <350 cells/μL or an AIDS diagnosis within 24 weeks of enrolment, the percentage of individuals who could not be classified as late presenters or non-late presenters was 6.1%, while it was around 4% when the window was modified to 4, 12 or 48 weeks (S2 Table). While considering different windows of time, similar prevalence was observed for LP (range: 44.6–45.0%) and for LPAD (range: 26.3–26.6%) (S2 Table). Highly consistent results were observed for the association between individual characteristics and LP and LPAD and on the risk of experiencing events of the composite endpoint and its components (S3 and S4 Tables).

Discussion

This cohort study demonstrates that LP remains a major health issue in Spain. We observed a LP prevalence of 44.8% for the whole study period (2004–2018), and although a reduction was observed in 2009–2012, current data show a trend towards stabilization since then. We also observed a negative impact of both LP and LPAD on the occurrence of clinical outcomes, including ADE, SNAE and death.

We observed a similar LP prevalence in a previous CoRIS study [5], consistent with data from studies in the COHERE’s Europe region [18, 19] as well as in other European studies. (France 48% [1], Italy 54% [2], Belgium 44% [3], Germany 58% [20], Switzerland 45% [21]). Similarly, the LPAD prevalence of 26% was close to the one observed in Belgium (24%, [3]), but slightly lower than the one described in the European region (33% [18, 19]) and in other nearby countries (France 29% [1], Italy 37% [2], Germany 36% [20]). Despite the decreasing trend from 2004–2008 to 2009–2012 and the publication in 2014 of the national guidelines on early HIV diagnosis [7], our estimates show a trend towards stabilization since then. The reasons why the prevalence of LP has stopped decreasing may be linked to the persistent low HIV testing frequency in Spain, which is around 20% [22]. This low rate may be due on one hand to the lack of awareness about HIV infection, the stigma as well as the lack of knowledge about health care services, and on the other hand to the lack of testing offer by the healthcare providers [22]. Promoting HIV testing should increase early HIV diagnosis in Spain.

The still high LP prevalence observed in our study may result from the influence of those factors classically associated with LP itself. As detected in other studies performed in geographically closely related regions [1, 2, 19, 20, 23, 24]. HIV acquisition mechanisms other than homosexual contact, as well as older age, low educational level and migrant status are consistently risk factors for LP and LPAD throughout the period. With respect to the HIV exposure group, a low self-perceived HIV-risk may be the reason why LP prevalence is higher among heterosexuals and those whose acquisition mechanism is unknown [25]. Furthermore, although IDU remains an important risk factor for LP, we observed that IDUs had the greatest decrease in LP prevalence, as observed in other studies [2, 5], which might be the consequence...
of an active engagement and linkage to care in centers designed for harm reduction programs in Spain. Consistent with data from CoRIS [5] and COHERE [26], we observed an increased risk of LP in participants with lower educational level. A higher educational level is associated with a more frequent access and use of health services; it may also be associated with increased health literacy and cognitive skills that improve health-related choices [26]. Furthermore, Fakoya I et al. [27] found that migrants had good access to primary care once they arrived in Europe and before their first positive HIV test, but language difficulties, lack of social support and cultural background (i.e.: the use of traditional medicine in the home country) were barriers to more frequent HIV testing and prevention after their arrival. [27, 28]. Díaz A et al. [29] demonstrated that risk of LP was stronger among migrants with low compared to high educational level in a Spanish sexually transmitted infections center.

Thus, we have found that the prevalence of late diagnosis remains high, especially in the most vulnerable group of patients, and that it has not decreased despite the publication of national guidelines on early HIV diagnosis [7]. This may be due in part to the difficulty of implementing recommendations as well as to the lack of resources [30]. For example, the quasi-experimental study ESTVIH [31] evaluated the feasibility of the application of different HIV diagnosis strategies in six Spanish primary care centers. Although healthcare workers expressed a high degree of interest in participating, only 26% of them recruited patients mainly because of the lack of time. Nevertheless, those trained to give pre and post-test counselling ordered the most tests [31]. A targeted strategy to identify persons with increased HIV risk has been proposed through the Drive 01 study [32]. The authors validated a structured questionnaire to assess HIV risk of exposure and indicator conditions specific to Spain, that predicted at 100% those individuals without infection and, if applied, it would make the test offer more efficient.

In terms of the clinical impact of LP, we found higher incidence rates for the composite endpoint and for ADE, SNAE and deaths both in patients presenting late compared to those with non-LP and in patients presenting with advanced disease, compared to those with non-LPAD. To the best of our knowledge, there is no other large cohort study which separately addresses ADE, SNAE and deaths.

Consistent with our results, researchers from the Dutch Athena cohort [33] and the MASTER cohort [34] observed an increased risk for the composite endpoint in participants with poor immune recovery.

As expected, the risk for ADE was higher in both the LP and the LPAD subgroups than in the non-LP and non-LPAD ones. Similarly, an Italian cohort [2] detected a reduction in LP mortality since the introduction of ART, which reflects the better management of frequent ADEs in these subgroups when the viral load is suppressed on ART.

Both LP and LPAD were associated with an increased risk for SNAE, compared with their counterparts. In the same cohort, Masía et al. [35] observed that the presence of ADE and the baseline CD4 count were risk factors for the development of SNAE and consequent overall mortality. Similarly, results from the D:A:D cohort showed that both last and nadir CD4 count were independent predictors of mortality due to ADE and SNAE [36]. Mocroft et al. [37] observed that a low CD4 count (<350 cells/μL) was associated with an increased risk of ADE or SNAE in patients from the EuroSIDA cohort. Possible mechanisms for the development of SNAE in LP [34] and LPAD [38] may be poor immune dysfunction, greater immune activation or persistent inflammation and oxidative stress. However, when interpreting these findings, it must be taken into account that there is great variability in SNAE definitions across studies, so results may not be directly comparable.

In terms of specific SNAE, consistent with our findings, Reekie et al. [39] found an increased incidence of some non-AIDS related cancers in patients with lower current CD4
count within the EuroSIDA Cohort. Impaired immunity could be certainly playing a role, as CD4 count depletion is associated with malignancy [40]. Moreover, CoRIS late presenter patients are older, and ageing-related immunosenescence is also linked with malignancies.

It may be argued that the association between LP and SNAE is confounded by age, which is a known risk factor for both conditions. For this reason, all our multivariable models are adjusted for age. Besides, Mocroft et al. [41] showed that the impact of high HIV progression risk (CD4 count $\leq 350$ cells/$\mu$L, viral load $\geq 10,000$ copies/mL) vs low (CD4 count $\geq 500$ cells/$\mu$L, viral load $< 50$ copies/mL) was greater in patients aged less than 30 years than in older patients. These findings highlight the important role of HIV infection in SNAE development even in groups with low risk of comorbidities development, such as young patients. Finally, we also observed an association between LP and LPAD and death from all causes. This finding is consistent with what was previously observed in the CoRIS cohort [5] especially for LPAD, with findings from Ingle et al [9].

The main strength of our study lies in being based on CoRIS, a large national cohort representative of the epidemiological situation of HIV-infected individuals in Spain. Furthermore, to the best of our knowledge, there is no other large cohort study which separately addresses ADE, SNAE and deaths, and the composite endpoint studied in relation to the LP and LPDA.

Our study has some limitations. First, we could not include all new HIV diagnoses in our analysis because 4% of cases lack information on CD4 count or ADE. Furthermore, LP prevalence may be overestimated because of a misclassification due to low CD4 count during acute HIV infection [42]. In addition, due to the low number of individuals experiencing some specific SNAE such as kidney events, these results should be interpreted with caution.

In conclusion, LP remains a major problem in Spain, with higher prevalence among certain populations, and is associated with greater morbidity and mortality. Public policies should be implemented to expand screening and early diagnosis of HIV infection for a focus on those at greatest risk of late presentation. As an example, targeted diagnostic programs could be run in emergency department, primary care and other medical centers; HIV testing could be considered as a priority in primary care protocols and information campaigns aimed at medical professionals could be carried out to publicize and improve the application of clinical guidelines.

Supporting information

S1 Fig. Flowchart of population selection.
(DOCX)

S1 Table. Independent risk factors for late presentation and late presentation with advanced disease by time-period.
(DOCX)

S2 Table. Prevalence of late presentation and late presentation with advanced disease when late presentation is defined as an HIV-diagnosis at a CD4 $< 350$/$\mu$L (or $< 200$/$\mu$L for advanced disease) or an AIDS-defining event within the 4, 12 or 48 weeks after enrolment by time-period (2004–2008, 2009–2012 and 2013–2018).
(DOCX)

S3 Table. Independent risk factors associated with late presentation and late presentation with advanced disease when late presentation is defined as an HIV-diagnosis at a CD4 $< 350$ cells/$\mu$L (or $< 200$ cells/$\mu$L for advanced disease) or an AIDS-defining event within the 4, 12 or 48 weeks after enrolment.
(DOCX)
S4 Table. Impact of late presentation and late presentation with advanced disease on the composite endpoint, first ADE, first SNAE and overall mortality when late presentation and late presentation with advanced disease are defined as participants with an HIV-diagnosis at a CD4<350 cells/µL (or <200 cells/µL for advanced disease) or with an AIDS-defining event within the 4, 12 or 48 weeks after enrolment. S4 Table. Impact of late presentation and late presentation with advanced disease on the composite endpoint, first AIDS event, first serious non-AIDS event and overall mortality when late presentation and late presentation with advanced disease are defined as participants with an HIV-diagnosis at a CD4<350 cells/µL (or <200 cells/µL for advanced disease) or with an AIDS-defining event within the 4, 12 or 48 weeks after enrolment.

(DOCX)

Acknowledgments

This study would not have been possible without the collaboration of all patients, medical and nursery staff and data managers who have taken part in the Project.

Executive committee

Santiago Moreno, Inma Jarrín, David Dalmau, Maria Luisa Navarro, María Isabel González, Federico García, Eva Poveda, Jose Antonio Iribarren, Félix Gutiérrez, Rafael Rubio, Francesc Vidal, Juan Berenguer, Juan González, M Ángeles Muñoz-Fernández.

Fieldwork data management and analysis

Inmaculada Jarrín, Belén Alejos, Cristina Moreno, Carlos Iniesta, Luis Miguel García Sousa, Nieves Sanz Perez, Marta Rava.

BioBanK HIV Hospital General Universitario Gregorio Marañón

M Ángeles Muñoz-Fernández, Irene Consuegra Fernández.

Hospital General Universitario de Alicante (Alicante)

Esperanza Merino, Gema García, Irene Portilla, Iván Agea, Joaquín Portilla, José Sánchez-Payá, Juan Carlos Rodríguez, Lina Gimeno, Livia Giner, Marcos Díez, Melissa Carreres, Sergio Reus, Vicente Boix, Diego Torrús.

Hospital Universitario de Canarias (San Cristóbal de la Laguna)

Ana López Lirola, Dácil García, Felicitas Díaz-Flores, Juan Luis Gómez, María del Mar Alonso, Ricardo Pelazas, Jehovana Hernández, María Remedios Alemán, María Inmaculada Hernández.

Hospital Universitario Central de Asturias (Oviedo)

Víctor Asensi, Eulalia Valle, María Eugenia Rivas Carmenado, Tomás Suárez-Zarracina Secades, Laura Pérez Is.

Hospital Universitario 12 de Octubre (Madrid)

Rafael Rubio, Federico Pulido, Otilia Bisbal, Asunción Hernando, Lourdes Domínguez, David Rial Crestelo, Laura Bermejo, Mireia Santacreu.

Hospital Universitario Donostia (Donostia-San Sebastián)

José Antonio Iribarren, Julio Arrizabalaga, María José Aramburu, Xabier Camino, Francisco Rodríguez-Arondo, Miguel Ángel von Wichmann, Lidia Pascual Tomé, Miguel Ángel Goenaga, Mª Jesús Bustinduy, Harkaitz Azkune, Maialen Ibargurein, Aitziber Lizardi, Xabier Kortajarena, Mª Pilar Carmona Oyaga, Maitane Umerez Igartua.

Hospital Universitario De Elche (Elche)

Félix Gutiérrez, Mar Masía, Sergio Padilla, Catalina Robledano, Joan Gregori Colomé, Arazeli Adsuar, Rafael Pascual, Marta Fernández, José Alberto García, Xavier Barber, Vanessa Agullo Re, Javier Garcia Abellán, Reyes Pascual Pérez, María Roca.

Hospital Universitari Germans Trias i Pujol (Can Ruti) (Badalona)
Roberto Muga, Arantza Sanvisens, Daniel Fuster.

**Hospital General Universitario Gregorio Marañón (Madrid)**
Juan Berenguer, Juan Carlos López Bernaldo de Quirós, Isabel Gutiérrez, Margarita Ramírez, Belén Padilla, Paloma Gijón, Teresa Aldamiz-Echevarría, Francisco Tejerina, Francisco José Parras, Pascual Balsalobre, Cristina Diez, Leire Pérez Latorre, Chiara Fanciulli.

**Hospital Universitari de Tarragona Joan XXIII (Tarragona)**
Francesc Vidal, Joaquín Peraire, Consuelo Viladés, Sergio Veloso, Montserrat Vargas, Montserrat Otona, Anna Rull, Esther Rodríguez-Gallego, Verónica Alba, Alfonso Javier Castellanos, Miguel López-Dupla.

**Hospital Universitario y Politécnico de La Fe (Valencia)**
Marta Montero Alonso, José López Aldeguer, Marino Blanes Juliá, María Tasis Pitarch, Iván Castro Hernández, Eva Calabuig Muñoz, Sandra Cuéllar Tovar, Miguel Salavert Lleti, Juan Fernández Navarro.

**Hospital Universitario La Paz/IdiPAZ**
Ignacio de los Santos, Jesús Sanz Sanz, Ana Salas Aparicio, Cristina Sarria Cepeda, Lucio García-Fraile Fraile, Enrique Martín Gayo.

**Hospital General Universitario Reina Sofía (Murcia)**
Enrique Bernal, Alfredo Cano Sanchez, Antonia Alcaraz García, Joaquín Bravo Urbieto, Ángeles Muñoz Perez, Maria Jose Alcaraz, Maria del Carmen Villalba.

**Hospital Nuevo San Cecilio (Granada)**
Juan Berenguer, Juan Carlos López Bernaldo de Quirós, Isabel Gutiérrez, Margarita Ramírez, Belén Padilla, Paloma Gijón, Teresa Aldamiz-Echevarría, Francisco Tejerina, Francisco José Parras, Pascual Balsalobre, Cristina Diez, Leire Pérez Latorre, Chiara Fanciulli.

**Hospital Universitari de Tarragona Joan XXIII (Tarragona)**
Francesc Vidal, Joaquín Peraire, Consuelo Viladés, Sergio Veloso, Montserrat Vargas, Montserrat Otona, Anna Rull, Esther Rodríguez-Gallego, Verónica Alba, Alfonso Javier Castellanos, Miguel López-Dupla.

**Hospital Universitario y Politécnico de La Fe (Valencia)**
Marta Montero Alonso, José López Aldeguer, Marino Blanes Juliá, María Tasis Pitarch, Iván Castro Hernández, Eva Calabuig Muñoz, Sandra Cuéllar Tovar, Miguel Salavert Lleti, Juan Fernández Navarro.

**Hospital Universitario La Paz/IdiPAZ**
Juan González-García, Francisco Arnalich, José Ramón Arribas, Jose Ignacio Bernardino de la Serna, Juan Miguel Castro, Ana Delgado Hierro, Luis Escosa, Pedro Herranz, Víctor Hontañón, Silvia García-Bujalance, Milagros García López-Hortelano, Alicia González-Baeza, María Luz Martín-Carbonero, Mario Mayoral, María Jose Mellado, Rafael Esteban Micán, Rocío Montejo, María Luisa Montes, Victoria Moreno, Ignacio Pérez-Valero, Guadalupe Rúa Cebrián, Berta Rodés, Talia Sainz, Elena Sendagorta, Natalia Stella Alcáriz, Eulalia Valencia.

**Hospital San Pedro Centro de Investigación Biomédica de La Rioja (CIBIR) (Logroño)**
José Ramón Blanco, José Antonio Oteo, Valvanera Ibarra, Luis Metola, Mercedes Sanz, Laura Pérez-Martínez.

**Hospital Universitario Miguel Servet (Zaragoza)**
Piedad Arazo, Gloria Sampériz.

**Hospital Universitari MutuaTerrassa (Terrassa)**
David Dalmay, Angels Jaén, Montse Sanmartí, Mireia Cairó, Javier Martinez-Lacasa, Pablo Velli, Roser Font, Marina Martinez, Francesco Aiello

**Complejo Hospitalario de Navarra (Pamplona)**
María Rivero Marcotegui, Jesús Repáraz, María Gracia Ruiz de Alda, María Teresa de León Cano, Beatriz Pierola Ruiz de Galarreta.

**Corporación Sanitaria Parc Taulí (Sabadell)**
Maria José Amengual, Gemma Navarro, Manel Cervantes García, Sonia Calzado Isbert, Marta Navarro Vilasaro.

**Hospital Universitario de La Princesa (Madrid)**
Ignacio de los Santos, Jesús Sanz Sanz, Ana Salas Aparicio, Cristina Sarria Cepeda, Lucio García-Fraile Fraile, Enrique Martín Gayo.

**Hospital Universitario Ramón y Cajal (Madrid)**
Santiago Moreno, José Luis Casado Osorio, Fernando Dronda Nuñez, Ana Moreno Zamora, María Jesús Pérez Eías, Carolina Gutiérrez, Nidia Madrid, Santos del Campo Terrón, Sergio Serrano Villar, María Jesús Vivancos Gallego, Javier Martínénez Sanz, Usua Anxa Urroz, Tamara Velasco.

**Hospital General Universitario Reina Sofía (Murcia)**
Enrique Bernal, Alfredo Cano Sanchez, Antonia Alcaraz García, Joaquín Bravo Urbieto, Ángeles Muñoz Perez, Maria Jose Alcaraz, Maria del Carmen Villalba.

**Hospital Nuevo San Cecilio (Granada)**
Federico García, José Hernández Quero, Leopoldo Muñoz Medina, Marta Alvarez, Natalia Chueca, David Vinuesa García, Clara Martínez-Montes, Carlos Guerrero Beltrán, Adolfo de Salazar Gonzalez, Ana Fuentes Lopez.

**Centro Sanitario Sandoval (Madrid)**
Jorge Del Romero, Montserrat Raposo Utrilla, Carmen Rodríguez, Teresa Puerta, Juan Carlos Carrión, Mar Vera, Juan Ballesteros, Oskar Ayerdí.

**Hospital Clínico Universitario de Santiago (Santiago de Compostela)**
Antonio Antela, Elena Losada.

**Hospital Universitario Son Espases (Palma de Mallorca)**
Melchor Riera, María Peñaranda, Mª Ángeles Ribas, Antoni A Campins, Carmen Vidal, Francisco Fanjul, Javier Murillas, Francisco Homar, Helem H Vilchez, María Luisa Martin, Antoni Payeras.

**Hospital Universitario Virgen de la Victoria (Málaga)**
Jesús Santos, Cristina Gómez Ayerbe, Isabel Viciana, Rosario Palacios, Carmen Pérez López, Carmen María González-Domenec.

**Hospital Universitario Virgen del Rocío (Sevilla)**
Pompeyo Viciana, Nuria Espinosa, Luis Fernando López-Cortés.

**Hospital Universitario de Bellvitge (Hospitalet de Llobregat)**
Daniel Podzamczar, Arkaitz Imaz, Juan Tiraboschi, Ana Silva, María Saumoy, Paula Prieto.

**Hospital Universitario Valle de Hebrón (Barcelona)**
Esteban Ribera, Adrian Curran.

**Hospital Costa del Sol (Marbella)**
Julián Olalla Sierra, Javier Pérez Stachowski, Alfonso del Arco, Javier de la torre, José Luis Prada, José María García de Lomas Guerrero.

**Hospital General Universitario Santa Lucía (Cartagena)**
Onofre Juan Martínez, Francisco Jesús Vera, Lorena Martínez, Josefina García, Begoña Alcaraz, Amaya Jimeno.

**Complejo Hospitalario Universitario a Coruña (A Coruña)**
Ángeles Castro Iglesias, Berta Pernas Souto, Álvaro Mena de Cea.

**Hospital Universitario Basurto (Bilbao)**
Josefa Muñoz, Miren Zuriñe Zubero, Josu Mirenara Bataia-Etxaburu, Sofía Ibarra Ugarte, Oscar Luis Ferrero Benitez, Josefina López de Munain, Mª Mar Câmara López, Mireia de la Peña, Miriam Lopez, Íñigo Lopez Azkarreta.

**Hospital Universitario Virgen de la Arrixaca (El Palmar)**
Carlos Galera, Helena Albeníz, Aurora Pérez, Asunción Iborra, Antonio Moreno, María Angustias Merlos, Asunción Vidal, Marisa Meca.

**Hospital de la Marina Baixa (La Vila Joiosa)**
Concha Amador, Francisco Pasquau, Javier Ena, Concha Benito, Vicenta Fenoll, Concepción Gil Anguita, José Tomás Algado Rabasa.

**Hospital Universitario Infanta Sofía (San Sebastián de los Reyes)**
Inés Suárez-García, Eduardo Malmierca, Patricia González-Ruano, Dolores Martín Rodrigo, Mª Pilar Ruiz Seco.

**Hospital Universitario de Jaén (Jaén)**
Mohamed Omar Mohamed-Balghata, María Amparo Gómez Vidal.

**Hospital San Agustín (Avilés)**
Miguel Alberto de Zarraga.

**Hospital Clínico San Carlos (Madrid)**
Vicente Estrada Pérez, María Jesús Téllez Molina, Jorge Vergas García, Juncal Pérez-Somarrriba Moreno.
Hospital Universitario Fundación Jiménez Díaz (Madrid)
Miguel Górgolas, Alfonso Cabello, Beatriz Álvarez, Laura Prieto.

Hospital Universitario Príncipe de Asturias (Alcalá de Henares)
José Sanz Moreno, Alberto Arranz Caso, Cristina Hernández Gutiérrez, María Novella Mena.

Hospital Clínico Universitario de Valencia (València)
María José Galindo Puerto, Ramón Fernando Vilalta, Ana Ferrer Ribera.

Hospital Reina Sofía (Córdoba)
Antonio Rivero Román, Antonio Rivero Juárez, Pedro López López, Isabel Machuca Sánchez, Mario Frias Casas, Angela Camacho Espejo.

Hospital Universitario Severo Ochoa (Leganés)
Miguel Cervero Jiménez, Rafael Torres Perea.

Nuestra Señora de Valme (Sevilla)
Juan A Pineda, Pilar Rincón Mayo, Juan Macías Sanchez, Nicolás Merchante Gutierrez, Luis Miguel Real, Anaís Corma Gomez, Marta Fernández Fuertes, Alejandro Gonzalez Serna.

Hospital Álvaro Cunqueiro (Vigo)
Eva Poveda, Alexandre Pérez, Manuel Crespo, Luis Morano, Celia Miralles, Antonio Ocampo, Guillermo Pousada

Author Contributions

Conceptualization: Lourdes Domínguez-Domínguez, Otilia Bisbal, José-Antonio Iribarren, Rafael Rubio, Santiago Moreno, Inmaculada Jarrín.

Data curation: Marta Rava.

Formal analysis: Marta Rava.

Funding acquisition: José-Antonio Iribarren, Rafael Rubio.

Methodology: Marta Rava, Inmaculada Jarrín.

Resources: Santiago Moreno.

Supervision: Inmaculada Jarrín.

Writing – original draft: Marta Rava, Lourdes Domínguez-Domínguez, Otilia Bisbal.

Writing – review & editing: Marta Rava, Lourdes Domínguez-Domínguez, Otilia Bisbal, Luis Fernando López-Cortés, Carmen Busca, Antonio Antela, Patricia González-Ruano, Cristina Hernández, José-Antonio Iribarren, Rafael Rubio, Santiago Moreno, Inmaculada Jarrín.

References

1. Wilson KDA, Dray-Spira R, Aubrière C, Hamelin C, Spire B, Lert F. Frequency and correlates of late presentation for HIV infection in France: older adults are a risk group–results from the ANRS-VESPA2 Study, France. AIDS Care. 2014; 26: S83–S93. https://doi.org/10.1080/09540121.2014.906554 PMID: 24731147

2. Raffetti E, Postorino MC, Castelli F, Casari S, Castelnuovo F, Maggiolo F, et al. The risk of late or advanced presentation of HIV infected patients is still high, associated factors evolve but impact on overall mortality is vanishing over calendar years: results from the Italian MASTER Cohort. BMC Public Health. 2016; 16: 878. https://doi.org/10.1186/s12889-016-3477-z PMID: 27557878

3. Darcis G, Lambert I, Sauvage AS, Fripiat F, Meuris C, Uurlings F, et al. Factors associated with late presentation for HIV care in a single Belgian reference center: 2006–2017. Sci Rep. 2018. https://doi.org/10.1038/s41598-018-26852-0 PMID: 29872068
4. Agaba PA, Meloni ST, Sule HM, Agbajie OO, Ekeh PN, Job GC, et al. Patients who present late to HIV care and associated risk factors in Nigeria. HIV Med. 2014. https://doi.org/10.1111/hiv.12125 PMID: 24580742

5. Sobrino-Vegas P, Moreno S, Rubio R, Viciana P, Bernardino JI, Blanco JLJR, et al. Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004–2013. J Infect. 2016; 72: 587–596. https://doi.org/10.1016/j.jinf.2016.01.017 PMID: 26920789

6. Unidad de vigilancia del VIH, ITS y hepatitis. Actualización del Continuo de Atención del VIH en España, 2017–2019. Madrid: Centro Nacional de Epidemiología–Instituto de Salud Carlos III / Plan Nacional sobre el Sida–Dirección General de Salud Pública; 2020

7. Ministerio de Sanidad, Servicios Sociales e Igualdad, Plan Nacional sobre Sida, Guía de recomendaciones para el diagnóstico precoz de VIH en el ámbito sanitario, 2014

8. Smit C, Hallett TB, Lange J, Garnett G, de Wolf F. Late Entry to HIV Care Limits the Impact of Anti-Retroviral Therapy in the Netherlands. Maartens G, editor. PLoS One. 2008; 3: e1949. https://doi.org/10.1371/journal.pone.0001949 PMID: 18398473

9. Ingle SM, May MT, Gill MJ, Mugavero MJ, Lewden C, Abgrall S, et al. Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients. Clin Infect Dis. 2014. https://doi.org/10.1093/cid/ciu261 PMID: 24771333

10. Stirrup OT, Copas AJ, Phillips AN, Gill MJ, Geskus RB, Touloumi G, et al. Predictors of CD4 cell recovery following initiation of antiretroviral therapy among HIV-1 positive patients with well-estimated dates of seroconversion. HIV Med. 2018; 19: 184–194. https://doi.org/10.1111/hiv.12567 PMID: 29230953

11. Irene Hall H, Holtgrave DR, Maulsby C. HIV transmission rates from persons living with HIV who are aware and unaware of their infection. AIDS. 2012. https://doi.org/10.1097/QAD.0b013e328351f73f PMID: 22313960

12. Li Z, Purcell DW, Sansom SL, Hayes D, Hall HI. Vital signs: HIV transmission along the continuum of care—United States, 2016. Morb Mortal Wkly Rep. 2019. https://doi.org/10.15585/mmwr.mm6811e1 PMID: 30897075

13. Halperin J, Katz M, Pathmanathan I, Myers L, Van Sickels N, Seal PS, et al. Early HIV Diagnosis Leads to Significantly Decreased Costs in the First 2 Years of HIV Care in an Urban Charity Hospital in New Orleans. J Int Assoc Provid AIDS Care. 2017. https://doi.org/10.1177/232597417737381 PMID: 29076395

14. Caro-Murillo AM, Castilla J, Pérez-Hoyos S, Miró JM, Podzamczer D, Rubio R, et al. [Spanish cohort of naive HIV-infected patients (CoRIS): rationale, organization and initial results]. Enferm Infecct Microbiol Clin. 2007; 25: 23–31. https://doi.org/10.10117/13096749 PMID: 17261243

15. Antinori A, Coenen T, Costaglia D, Dedes N, Ellefson M, Gatell J, et al. Late presentation of HIV infection: a consensus definition. HIV Med. 2011; 12: 61–64. https://doi.org/10.1111/j.1468-1299.2010.00857.x PMID: 20561080

16. Zou G. A Modified Poisson Regression Approach to Prospective Studies with Binary Data. Am J Epidemiol. 2004; 159: 702–706. https://doi.org/10.1093/aje/kwh090 PMID: 15033648

17. R Core Team (2020). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/.

18. Mocroft A, Lundgren JD, Sabin ML, d’Arminio Monforte A, Brockmeyer N, Casabona J, et al. Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). Sansom SL, editor. PLoS Med. 2013; 10: e1001510. https://doi.org/10.1371/journal.pmed.1001510 PMID: 24137103

19. Berenguer J, Bohlius J, Bouteloup V, Bucher H, Cozzi-Lepri A, Dabis F, et al. Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. Eurosurveillance. 2015; 20: 7–18. https://doi.org/10.2807/1560-7917.es2015.20.25.21163 PMID: 26132767

20. Zoufaly A, an der Heiden M, Marcus U, Hoffmann C, Stellbrink HJ, Voss L, et al. Late presentation for HIV diagnosis and care in Germany. HIV Med. 2012; 13: 172–181. https://doi.org/10.1111/j.1468-1299.2011.00985.x PMID: 22093171

21. Buetikofer S, Wandelner G, Kouryos R, Weber R, Ledergerber B, Aubert V, et al. Prevalence and risk factors of late presentation for HIV diagnosis and care in a tertiary referral centre in Switzerland: Presenting late with HIV-1. Swiss Med Wkly. 2014. https://doi.org/10.4414/smw.2014.13961 PMID: 24723302

22. Teva I, de Araújo LF, de la Paz Bermúdez M. Knowledge and Concern about STIs/HIV and Sociodemographic Variables Associated with Getting Tested for HIV Among the General Population in Spain. J Psychol Interdiscip Appl. 2018. https://doi.org/10.1080/00223980.2018.1451815 PMID: 29652613
33. Van Lelyveld SFL, Gras L, Kesselring A, Zhang S, De Wolf F, Wensing AMJ, et al. Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort. AIDS. 2012. https://doi.org/10.1097/QAD.0b013e32835f2628 PMID: 22112603

34. Lapadula G, Chatenoud L, Gori A, Castelli F, Di Giambenedetto S, Fabbiani M, et al. Risk of severe non AIDS events is increased among patients unable to increase their CD4 + T-cell counts >200/μl despite effective HAART. PLoS One. 2015. https://doi.org/10.1371/journal.pone.0124741 PMID: 26020949

35. Masì M, Padilla S, Moreno S, Barber X, Iribarren JA, Del Romero J, et al. Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach. PLoS One. 2017; 12: e0184329. https://doi.org/10.1371/journal.pone.0184329 PMID: 28986092

36. d’Arminio Monforte A, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, et al. The impact of nontargeted HIV screening. Med (United States). 2016. https://doi.org/10.1097/MD.0000000000002612 PMID: 26844471

37. Mocroft A, Laut K, Reiss P, Gatei J, Ormaasen V, Cavassini M, et al. Where is the greatest impact of uncontrolled HIV infection on AIDS and non-AIDS events in HIV? AIDS. 2018. https://doi.org/10.1097/QAD.0000000000001684 PMID: 29112060
42. Sasse A, Florence E, Pharris A, De Wit S, Lacor P, Van Beckhoven D, et al. Late presentation to HIV testing is overestimated when based on the consensus definition. HIV Med. 2016; 17: 231–234. https://doi.org/10.1111/hiv.12292 PMID: 26222266